Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.40 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893019 | 0.81 | PTGER2 (0.37) | PTGER2PTGER3PTGER4PTGDR | |
| SCHEMBL9893023 | 0.80 | PER2 (0.46) | CNR2PTGER2PTGER3HSD11B1PTGDR | |
| SCHEMBL16480371 | 0.80 | PTGS2 (0.47) | PTGS2PTGS1CNR2GPR119HSD11B1 | |
| SCHEMBL9893157 | 0.80 | PTGER2 (0.42) | PTGER2PTGER3PTGER4PTGDR | |
| SCHEMBL9892975 | 0.80 | PTGER2 (0.44) | PTGER2PTGER3PTGER4PTGDR | |
| SCHEMBL9893017 | 0.78 | KMT2A (0.46) | — | |
| SCHEMBL9892976 | 0.78 | PTGER2 (0.41) | PTGER2PTGER3PTGER4PTGDR | |
| SCHEMBL9891735 | 0.77 | CNR2 (0.48) | PTGS2PTGS1CNR2GPR119HSD11B1 | |
| SCHEMBL9892973 | 0.77 | ELANE (0.43) | CNR2PTGER2PTGER3PTGER4PTGDR | |
| SCHEMBL9892985 | 0.77 | PTGER2 (0.48) | CNR2PTGER2PTGER3HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | PTGS2 240/4885PTGS1 175/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.